尿石素A Urolithin A × 肌少症

結論:證據分歧

尿石素A 在肌少症之證據停留在「機轉合理 + 少量人體研究、學會明確不背書」的薄弱層級:Examine 資料庫尚未收錄任何分級結果(No Study Database),兩篇關鍵 RCT(Singh 2022 中年人 n=88、Liu 2022 年長者 n=66)皆未達預先設定之主要終點(峰值功率、6MWD、ATPmax),陽性訊號(hamstring 約 +12%、VO2peak、肌耐力、發炎生物標記)全屬次級終點且存在多重比較問題;2025 medRxiv 系統性回顧(n=174)為 preprint 且明確指出證據不足、肌肉量未提升、且無 RCT 招募臨床定義之肌少症族群。

C 🟠 C 薄弱證據 證據分歧 ⚠️ medium — moderate promotional content

尿石素A 在肌少症之證據停留在「機轉合理 + 少量人體研究、學會明確不背書」的薄弱層級:Examine 資料庫尚未收錄任何分級結果(No Study Database),兩篇關鍵 RCT(Singh 2022 中年人 n=88、Liu 2022 年長者 n=66)皆未達預先設定之主要終點(峰值功率、6MWD、ATPmax),陽性訊號(hamstring 約 +12%、VO2peak、肌耐力、發炎生物標記)全屬次級終點且存在多重比較問題;2025 medRxiv 系統性回顧(n=174)為 preprint 且明確指出證據不足、肌肉量未提升、且無 RCT 招募臨床定義之肌少症族群。

三大相關學會(ESPEN/AGS/EWGSOP2)對 UA 一致沉默,國際監管端僅給予食品安全性背書(FDA GRAS 791、EFSA ≤500 mg/日、TGA Compositional Guideline、Health Canada NPN 80128555),無任何疾病療效核可。

Amazentis 為兩項關鍵 RCT 之資助者並擁有 UA 專利,COI 滲透核心證據鏈。

整體判讀為 Tier C(薄弱證據):不符合 Tier B 所需「≥1 quality MA + ≥3 一致 RCT」之門檻,但機轉清楚、安全性可接受、有正向但非首要終點之訊號,足以支撐「研究中之新興介入」之定位,無法支撐肌少症療效宣稱。

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.61
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 證據分歧
信心度
74%
證據方向大致一致
證據層級
E3
單篇高品質統合分析

各層「支持此療效」的程度

分數越低=該層越不支持
L1 Examine國際基準
0.50
L5 臨床機構權威立場
0.50
L11 AI 複核獨立判讀
0.50
L3 機轉生理合理性
0.65
L2 PubMed原始文獻
0.75
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.613
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高階證據未達主導 (0 positive vs 1 negative),由 raw_score 決定
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans
PMID: 32694802 2019 RCT (double-blind) n = 60
結論:Urolithin A had a favourable safety profile at all doses; 500 mg and 1000 mg/day for 4 weeks significantly modulated plasma acylcarnitines and induced a mitochondrial/cellular-health molecular signature in skeletal muscle (Phase I, no clinical muscle-strength endpoint).
⚠️ 廠商資助
前往 PubMed
Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial
PMID: 35050355 2022 RCT (double-blind) n = 66
結論:Primary endpoints not significant: 6MWD +60.8 m (UA) vs +42.5 m (placebo), p=NS; ATPmax no significant between-group difference. Secondary: muscle endurance (fatigue resistance) improved at 2 months in both hand FDI (p<0.01) and leg TA (p=0.05); plasma acylcarnitines, ceramides and CRP decreased with UA.
混合資助 效應量:6MWD between-group MD ~+18 m (NS); muscle endurance gains in fatigue-resistance test (secondary)
前往 PubMed
Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults
PMID: 35584623 2022 RCT (double-blind) n = 88
結論:Primary endpoint (peak power) NS. Secondary: hamstring strength improved ~12% vs placebo (p=0.027 at 500 mg; p=0.029 at 1000 mg); VO2peak significantly increased at 1000 mg (p<0.01); 6-min walk distance improved at 1000 mg (p<=0.008); plasma acylcarnitines and CRP decreased (p<0.05).
⚠️ 廠商資助 效應量:~12% hamstring strength gain (secondary); VO2peak between-group improvement at 1 g/day
前往 PubMed
Assessment of Urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind…
PMID: 39487653 2024 RCT (double-blind) n = 20
結論:MVIC increased significantly vs baseline in UA arm (Delta 36.10 NM, p<0.001); RTF improved (Delta +2.00, p=0.001); 3-methylhistidine decreased (p=0.049); CRP decreased vs placebo (p=0.032); 1RM bench/squat improvements NOT statistically significant. Very small (n=20) athletic — not a sarcopenia population.
🟠 品質有限 效應量:MVIC MD ~+36 NM within-group; RTF MD +2 reps
前往 PubMed
The effects of urolithin A supplementation on muscle strength, muscle mass and physical performance in humans - a systematic review (preprint, medRxiv)
PMID: 2025 系統性回顧 n = 174
— 詳細結論請見 PubMed 原文
前往 PubMed

L4a US FDA
支持
FDA has no questions 來源↗
L4b EU EFSA
中性
In 2022, the European Food Safety Authority (EFSA) gave a positive opinion on the safety of Urolithin A for use in food supplements for the general adult population. The EFSA report emphasized no adverse effects under the proposed daily dose of up to 500 mg/day. 來源↗
L4c UK NHS
未表態
Application for the approval of Urolithin A as a novel food. Applicant: Amazentis SA. Status: In progress. Current Phase: Risk assessment In progress. [ACNFP 173rd meeting, 24-25 Sept 2025] The applicant proposes urolithin A in conventional foods, cereal bars, protein bars, nutrition bars targeting athletes, yoghurt products, specialised foods for adults only, including meal replacements, nutri… 來源↗
L4d TW TFDA / 衛福部
未表態
— 本適應症無對應資料
L4e WHO
支持
Urolithin A is a synthetic version of urolithin A of the compound formed endogenously following consumption of ellagic acid and ellagitannins. Urolithin A is manufactured via chemical synthesis involving a chemical reaction between 2-bromo-5-hydroxybenzoic acid and resorcinol in the presence of sodium hydroxide and catalyst of cupric sulfate pentahydrate, followed by protonation of the resultin… 來源↗

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

PTT(健身/MuscleBeach/regimen/Health/Mancare)、Dcard(健身/美妝)、Mobile01 均無「尿石素A 用於肌少症」的在地真實使用心得討論串。此成分屬新興且偏冷門的進口保健品(主要為 Mitopure),台灣鄉民幾乎未討論。台語/中文搜尋結果以商業媒體(康健、IQ健康網、GeneOnline、BusinessWire)與新聞稿為主,並非社群經驗。唯一在地訊號是 Cofacts(真的假的)標記一則丁丁藥局「Mitopure 尿石素膠囊 促進海綿體細胞再生」的誇大不實廣告,反映行銷污染而非真實鄉民實測。

💬社群實感

無共識(台灣社群幾乎無針對肌少症的尿石素A實測心得)

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

Timeline Urolithin A 60 軟膠囊 $2,899

代表來源 ↗
L10b · TFDA 法定身份 官方認定

本平臺非正面表列,並非平臺未載列品項即不得供為食品原料使用

來源 ↗

  • 漸進式阻力訓練
  • 攝取足量蛋白質
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v6 engine_version: v1.0 claim_id: CLM-COND-sarcopenia-INT-urolithin-a-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-sarcopenia-INT-urolithin-a-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "尿石素A能改善肌少症",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 2,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟠 C 薄弱證據"
  }
}